Last week, Sun Pharmaceutical and AstraZeneca Pharma India entered into a distribution services agreement for AstraZeneca’s newly branded Axcer -- an updated version of AstraZenca's clot-fighting treatment, Brilinta.
AstraZeneca has been selling Brilinta in India since 2012. Under the terms of the collaboration, Sun Pharma will be promoting and distributing Axcer in India. According to Sun, this will enable AstraZeneca to expand usage of the molecule, while strengtheing Sun Pharma’s cardiology portfolio.
Both Brilinta and Axcer (Ticagrelor) work by preventing the formation of new blood clots and maintaining blood flow, helping reduce a patient’s risk of another heart attack.
Read the Economic Times press release